Panel: GLP-1s and the Next Wave in Obesity Therapies

Session details:

Novo Nordisk and Eli Lilly have redefined obesity treatment with blockbuster GLP-1 injectables, creating one of the fastest-growing drug markets in history. Now the field is shifting toward oral GLP-1s, dual and triple agonists, and a handful of novel mechanisms that could expand treatment options further. With patient demand soaring and the competitive bar set high, even small safety concerns or modest efficacy gaps can shift market fortunes overnight. This discussion will explore how pharma is approaching obesity’s next chapter—from pipeline bets and clinical trial design to the realities of competing in a market where expectations have never been higher.